Karim Abdelhamid

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Cross Sectional

Kidney Transplantation

Squamous Cell Carcinoma

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, Menno Pruijm, Solange Peters, Roger Hullin, Olivier Gaide, Guiseppe Pantaleo, Michel Obeid
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nature communications 15 (1) (2024)
Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, Menno Pruijm, Solange Peters, Roger Hullin, Olivier Gaide, Guiseppe Pantaleo, Michel Obeid
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nature communications 15 (1) (2024)
Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, Menno Pruijm, Solange Peters, Roger Hullin, Olivier Gaide, Guiseppe Pantaleo, Michel Obeid
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nature communications 15 (1) (2024)
Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, Menno Pruijm, Solange Peters, Roger Hullin, Olivier Gaide, Guiseppe Pantaleo, Michel Obeid
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nature communications 15 (1) (2024)
Victor Joo, Karim Abdelhamid, Alessandra Noto, Sofiya Latifyan, Federica Martina, Douglas Daoudlarian, Rita De Micheli, Menno Pruijm, Solange Peters, Roger Hullin, Olivier Gaide, Guiseppe Pantaleo, Michel Obeid
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma. Nature communications 15 (1) (2024)